Naurex Inc.
Lee Bastin has worked as the Director of Clinical Research for Naurex, Inc., Naurex, and NAUREX, INC. from an unknown start date to an unknown end date.
Lee Bastin received an ED. D. degree in Health/Health Care Administration/Management from North Carolina State University. Lee pursued this degree from 1995 to 1999.
This person is not in any teams
Naurex Inc.
Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs),which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators.